Search results
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,229.00
ETF DAILY NEWS· 7 days agoRegeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price upped by Royal Bank of Canada from $1,200.00 to $1,229.00 in a research report sent to investors ...
Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells 9,064 Shares of Stock
ETF DAILY NEWS· 6 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) CEO Leonard S. Schleifer sold 9,064 shares of the company’s stock in a transaction on Tuesday, June 11th. Following ...
Oracle Alpha Inc. Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 5 days agoOracle Alpha Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the fourth quarter, Holdings Channel reports. The ...
Teachers Retirement System of The State of Kentucky Sells 1,245 Shares of Regeneron Pharmaceuticals,...
ETF DAILY NEWS· 3 days agoTeachers Retirement System of The State of Kentucky cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.7% during the 4th quarter, according ...
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Investor's Business Daily· 6 days agoIt's been a decade since the last innovation in treating chronic obstructive pulmonary disease, or...
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past...
Simply Wall St. via Yahoo Finance· 5 days agoWhen you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and...
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market - ...
Benzinga· 6 days agoAnalyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
...Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc....
Benzinga· 4 days agoNEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). Such investors are
Diana Taurasi has some thoughts about how male journalists treat WNBA rookies and we're LIVING
Pride· 1 day agoOutside of the court, she’s also recently partnered with both Sanofi and Regeneron Pharmaceuticals...
How Managing Eczema Became a Slam Dunk for WNBA Star Diana Taurasi
Healthline via AOL· 2 days agoWNBA legend Diana Taurasi (above) is sharing how she learned to manage painful eczema flair-ups....